GYH Led Face Light Therapy Mask, Red Light Therapy Lamp LED Face Mask Professional, Blue Infrared Light Therapy, Wireless&Comfortable, Anti Aging & Anti Wrinkle, Cloud-S (RB-001)

Product Information

May 2015, delivered the Founders Lecture at the HeartRhythm Society meeting (theworld’s largest arrhythmia meeting) in Boston, USA Regularly acts as evaluator for academic promotion applicantsof national/international universities [multiple times eg. Hong Kong, Amsterdam, Athens, Israel (all 2012-)]. June 2016: Martin Green Lecture, Ottawa Heart Research Conference 2016: Translational Research in Atrial Fibrillation Paquette M, Riou França L, Teutsch C, Diener HC, Lu S, Dubner SJ, Ma CS, Rothman KJ, Zint K, Halperin JL, Huisman MV*, Lip GYH*, Nieuwlaat R*. Persistence With Dabigatran Therapy at 2Years in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017 Sep 26;70(13):1573-1583 [*joint senior authors]. Lip GYH, Freedman B, de Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: past, present and future comparing the guidelines and practical decision-making. Thromb Haemost 2017;117:1230–9.

Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 2014;129:837–47. Regular Guest Editor for ‘Circulation’ (2009-). Associate Editor for ‘Europace’ (the main journal for the European Heart Rhythm Association; 2009-). On the editorial boards of many of the main journals in the field, including the following (all with Impact Factor >4.0): Journal of the American College of Cardiology, European Heart Journal, Circulation, Atherosclerosis Thrombosis & Vascular Biology, Heart, American Journal of Cardiology, American Heart Journal, Chest, American Journal of Medicine, etc.Wang YF, Jiang C, He L, Du X, Sang CH, Long DY, et al. Integrated Care of Atrial Fibrillation Using the ABC (Atrial fibrillation Better Care) Pathway Improves Clinical Outcomes in Chinese Population: An Analysis From the Chinese Atrial Fibrillation Registry. Front Cardiovasc Med. 2021;8:762245.

Guo Y, Wang H, Zhang H, et al. Mobile photoplethysmographic technology to detect atrial fibrillation. J Am Coll Cardiol 2019;74:2365–75. Proietti M, Lip GYH, Laroche C, Fauchier L, Marin F, Nabauer M, et al. Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. Europace. 2020.

Prior allowances

September 2017, Polish Cardiac Society medal and awarded honorary membership of the society. XXI International Congress of the Polish Cardiac Society -Katowice, Poland. InJune 2014, ranked by Expertscapeas amongst the world's leading expert in the understanding and treatment of Hypertension. SteeringCommittee Chair on variousmulticentre clinical trials that bringresearch from industry to the UK. These include various Phase IItrials with new anticoagulants (eg. AZD0837, see PubMed PMID:19690349)and Phase III international trials (eg. ENSURE-AF, PMID:25965706), and registries (eg. GLORIA-AF, PMID: 26239094; PMID: 24576516).Professor Lip has also acted as UK lead investigator for international trials,with representation on trial steering committees (eg. PIONEER-AF, see PMID: 25819853) In this prospective cohort study including real-world AF patients, we found that patients adherent to the ABC pathway at baseline had a significantly lower risk of net clinical outcomes, all-cause mortality, and cardiovascular death. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119-26.

February 2017: Closing Ceremony Plenary Lecture, at 61 stAnnual Meeting of the Society of Thrombosis and Hemostasis Research (GTH), Basel, Switzerland, February 15 th– 18 th2017. RAF personnel can direct any questions, or obtain access to the ‘Direct Letter’ by approaching their allocated HR Team who, if necessary should seek further guidance from the Joint Personnel Administration Centre (JPAC) Enquiry Centre or your RAF Allowance Policy staff. Editor in Chief (Clinical Studies) [2010-] of ‘Thrombosis & Haemostasis’ (2016 Impact factor 5.627). Optimal stroke assessment and prevention requires a regular reassessment of stroke and bleeding risk, which is influenced by ageing or comorbidities. 19,20 Risk re-evaluation should be performed within 4 to 6 months after the first visit among AF patients with a low risk of stroke (CHA 2DS 2-VASc = 0 in men or 1 in women). Likewise, bleeding risk is highly dynamic and a high bleeding risk score (e.g. HAS-BLED ≥3) is not a reason for withholding OAC, but these patients should have proactive management of modifiable bleeding risk factors with scheduled early follow-up and review. 3,19,21November 2016, Key Note Speaker at National Institute for Preventive Cardiology of Ireland - National Prevention Meeting in Galway, Ireland. Added: Directed Letter - Operational allowance, campaign continuity allowance, and concessionary travel for immediate families interim arrangements in response to COVID-19. Research impact on improvements in healthcare is summarised in a University of Birmingham 2014 Research Excellence Framework (REF) Impact Case Study. October 2015, Opening Ceremony lecture 26 th Great Wall International Congress of Cardiology (GW-ICC) & Asia Pacific Heart Congress 2015 & International Congress Cardiovascular Prevention and Rehabilitation 2015